依折麦布联合瑞舒伐他汀在急性冠脉综合征患者中的应用效果  

Application Effect of Ezetimibe Combined with Rosuvastatin in Patients with Acute Coronary Syndrome

作　　者：曾国良[1] 彭宇团 黄杰雄[1] 邓斌[1] 罗伶俐[1] 黄楚梅[1] ZENG Guoliang;PENG Yutuan;HUANG Jiexiong;DENG Bin;LUO Lingli;HUANG Chumei(Department of Cardiology,the First People's Hospital of Zhaoqing,Zhaoqing 526060,China;不详)

机构地区：[1]肇庆市第一人民医院心内科,广东肇庆526060

出　　处：《中国医学创新》2024年第36期30-33,共4页Medical Innovation of China

基　　金：肇庆市科技计划项目(2021040307015)。

摘　　要：目的:探讨联用依折麦布及瑞舒伐他汀在急性冠脉综合征(ACS)中的疗效。方法:选取肇庆市第一人民医院2021年10月—2023年8月收治的156例ACS患者,按随机数字表法分为两组,各78例。对照组予瑞舒伐他汀治疗,观察组加用依折麦布治疗。比较两组血清血脂四项、超敏C反应蛋白(hs-CRP)水平,并记录不良反应发生情况。结果:治疗6周及3、12个月后,观察组甘油三酯、低密度脂蛋白胆固醇、总胆固醇、hs-CRP均低于对照组,高密度脂蛋白胆固醇均高于对照组,差异均有统计学意义(P<0.05);两组治疗6周及3、12个月后的不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:联用依折麦布及瑞舒伐他汀可更好地改善ACS患者血脂,降低hs-CRP水平,安全性良好。Objective:To investigate the efficacy of Ezetimibe combined with Rosuvastatin in patients with acute coronary syndrome (ACS). Method: A total of 156 patients with ACS treated in the First People's Hospital of Zhaoqing from October 2021 to August 2023 were selected and divided into two groups according to random number table method, with 78 cases in each group. The control group was treated with Rosuvastatin, and the observation group was additionally treated with Ezetimibe. The levels of serum blood lipid four items and hypersensitive C reactive protein (hs-CRP) were compared between the two groups, and the adverse reactions were recorded. Result: After 6 weeks and 3 and 12 months of treatment, triglyceride, low-density lipoprotein cholesterol, total cholesterol and hs-CRP in observation group were lower than those in control group, and high-density lipoprotein cholesterol were higher than those in control group, the differences were statistically significant (P<0.05). There were no significant differences in the incidences of adverse reactions between the two groups after 6 weeks and 3 and 12 months of treatment (P>0.05). Conclusion: Combined use of Ezetimibe and Rosuvastatin can better improve blood lipids of ACS patients and reduce the level of hs-CRP, with good safety.

关 键 词：急性冠脉综合征 依折麦布 瑞舒伐他汀 血脂四项 超敏C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]